BackKiniksa Pharmaceuticals International Plc. Overview

Kiniksa Pharmaceuticals International Plc. Current Assets

Kiniksa Pharmaceuticals International Plc.'s current assets is $590M.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$594.17M
66.95% YoYΔ $238.26M vs prior year quarter

Peer average

Loading

Kiniksa Pharmaceuticals International Plc. Current Assets History

Loading

Kiniksa Pharmaceuticals International Plc. vs. peers: Current Assets Comparison

Loading

Kiniksa Pharmaceuticals International Plc. Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Kiniksa Pharmaceuticals International Plc. (KNSA) FAQ

Kiniksa Pharmaceuticals International Plc. posts a current assets of $590M as of March 2026. That compares with $360M in the prior-year period — up 66.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Kiniksa Pharmaceuticals International Plc.'s current assets was $360M. The latest reading is $590M — a 66.9% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Current Assets is one piece of Kiniksa Pharmaceuticals International Plc.'s financial statement story. At $590M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for KNSA's current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Kiniksa Pharmaceuticals International Plc.'s other metric pages and overview cover the third.

Judging Kiniksa Pharmaceuticals International Plc. against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in current assets easier to interpret. Start with $590M here, then scan peer and history charts to see if the gap is persistent.